Bioinformant

At LineaRX, putting the horsepower behind the CAR T

By GREGORY ZELLER // Marking a big step in the war against cancer, a Stony Brook-based startup has initiated pre-clinical development of a non-viral, plasmid-free chimeric antigen receptor modified T-cell manufacturing platform. In English: A novel platform designed to develop and manufacture new pharmaceutical treatments, including treatments for different forms of cancer. The tech comes from LineaRx Inc., a wholly owned subsidiary that officially spun off from Stony Brook-based Applied DNA Sciences in September. Noting…